Natera, Inc. (NASDAQ:NTRA) Insider Sells $4,101,319.17 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 24,861 shares of the firm’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $4,101,319.17. Following the transaction, the insider now directly owns 140,684 shares in the company, valued at approximately $23,208,639.48. This represents a 15.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, December 9th, Solomon Moshkevich sold 4,858 shares of Natera stock. The shares were sold at an average price of $166.59, for a total value of $809,294.22.
• On Monday, October 28th, Solomon Moshkevich sold 1,196 shares of Natera stock. The shares were sold at an average price of $118.21, for a total value of $141,379.16.

Natera Trading Down 2.5 %

Shares of Natera stock opened at $167.61 on Monday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a 1 year low of $62.96 and a 1 year high of $183.00. The company has a market capitalization of $22.13 billion, a P/E ratio of -95.23 and a beta of 1.65. The business has a 50 day moving average price of $166.20 and a 200 day moving average price of $136.43.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.31. The company had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera’s revenue was up 63.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.95) EPS. Sell-side analysts anticipate that Natera, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Trading of Natera

Several institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP grew its stake in shares of Natera by 205.4% during the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after buying an additional 1,883,481 shares during the period. Massachusetts Financial Services Co. MA grew its stake in shares of Natera by 3.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company’s stock valued at $315,194,000 after buying an additional 85,236 shares during the period. Geode Capital Management LLC boosted its position in Natera by 7.4% during the 3rd quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock worth $265,747,000 after purchasing an additional 143,825 shares during the period. Duquesne Family Office LLC boosted its position in Natera by 2.4% during the 2nd quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock worth $213,860,000 after purchasing an additional 45,500 shares during the period. Finally, Maverick Capital Ltd. boosted its position in Natera by 25.2% during the 3rd quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company’s stock worth $170,119,000 after purchasing an additional 269,706 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

NTRA has been the topic of a number of analyst reports. Morgan Stanley lifted their price objective on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. Canaccord Genuity Group lifted their price objective on Natera from $165.00 to $180.00 and gave the company a “buy” rating in a report on Friday, January 3rd. Piper Sandler lifted their price objective on Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, November 18th. Barclays assumed coverage on Natera in a report on Thursday. They issued an “overweight” rating and a $200.00 price objective on the stock. Finally, JPMorgan Chase & Co. lifted their price target on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $162.94.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.